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Abstract 
Practical relevance: Feline hypertension is a common disease in older cats that is frequently 
diagnosed in association with other diseases such as chronic kidney disease and hyperthyroidism 
(so-called secondary hypertension), although some cases of apparent primary hypertension are also 
reported. The clinical consequences of hypertension can be severe, related to ‘target organ damage’ 
(eye, heart and vasculature, brain and kidneys) and early diagnosis followed by appropriate 
therapeutic management should help reduce the morbidity associated with this condition. 
Clinical challenges: Despite being a common disease, routine blood pressure monitoring is 
generally performed infrequently, probably leading to under-diagnosis of feline hypertension in 
clinical practice. There is a need to: (i) ensure blood pressure is measured as accurately as possible 
with a reproducible technique, (ii) identify and monitor patients at risk of developing hypertension, 
(iii) establish appropriate criteria for therapeutic intervention and (iv) establish appropriate 
therapeutic targets. Based on current data, amlodipine besylate is the treatment of choice to manage 
feline hypertension and is effective in the majority of cats, but the dose needed to successfully 
manage hypertension varies between individuals. Some cats may require long-term adjuvant 
therapy and, rarely, additional therapy may be necessary for emergency management of 
hypertensive crises. 
Evidence base: These Guidelines are based on a comprehensive review of the currently available 
literature, and are aimed at providing practical recommendations to address the challenges of feline 
hypertension for veterinarians. There are many areas where more data is required which, in the 
future, will serve to confirm or modify some of the recommendations in these Guidelines. 
 
Introduction 
Systemic arterial hypertension (referred to simply as hypertension in this document) is a well-
recognised condition in cats, but probably remains significantly under-diagnosed. The clinical 
consequences of hypertension can be severe, due to target organ damage (TOD) affecting the eyes, 
heart, brain and kidneys1, and some damage may be irreversible. Unless marked TOD is detected, 
the presence of hypertension is unlikely to be immediately apparent. Therefore, more widespread 
routine monitoring of feline blood pressure (BP) would likely enable an earlier diagnosis of 
hypertension and facilitate the prompt provision of effective therapy to prevent TOD and hopefully 
reduce the morbidity associated with hypertension. 
Indirect measurement of BP in cats can be readily performed, although care is needed with both the 
choice and use of the equipment to ensure meaningful and accurate results are obtained. Systolic 
blood pressure (SBP) has been shown to increase with age in cats2 as does the risk of hypertension.3 
The majority of cats diagnosed with hypertension have other systemic disease(s) which may cause 
or contribute to the hypertension3,4, although in up to 20% of cases no underlying cause is found.5–7 
Cats with an underlying disease are often referred to as having ‘secondary hypertension’ although 
the relationship between the hypertension and the underlying disease may not always be 
understood. When secondary hypertension is found, there is a need to manage both the hypertension 
and the underlying disease concurrently.  
These Guidelines have been created to offer practitioners up to date information on the causes, 
clinical signs, diagnosis and management of feline hypertension, as well as practical advice on 
measurement of BP and interpretation of results. Where clinical studies and scientific data are not 
available, these Guidelines represent consensus opinion of this panel. 
Regulation of blood pressure 
Blood pressure (BP) is the product of cardiac output (CO), which in turn is the product of heart rate 
and stroke volume (HR ⨉ SV), and systemic vascular resistance (SVR). Thus: BP = HR ⨉ SV ⨉ 
SVR.  
In health, despite potential changes to blood volume, CO and SVR, complex neural and hormonal 
homeostatic mechanisms involving the brain, heart, vasculature and kidneys, combine with local 
tissue factors to maintain BP within a relatively narrow range (Figure 1). 
The predominant factor controlling SVR is arteriolar size, which is affected by many systemically 
circulating, local tissue and endothelial-derived factors (Figure 1).6 Blood volume is regulated by 
the kidneys, mainly through pressure natriuresis and the renin angiotensin aldosterone system 
(RAAS). Pressure natriuresis couples water and sodium excretion in response to changes in blood 
volume and CO (through alterations in renal perfusion) while RAAS directly affects SVR via the 
potent vasoconstrictor angiotensin II, and affects blood volume through renal reabsorption of 
sodium and water via aldosterone. 
Some organs, including the kidney, have capacity to regulate their own BP (‘autoregulation’) to 
some extent. As a result, renal blood flow and glomerular filtration rate (GFR) are maintained over 
a range of SBPs (~80-160mmHg). Outside of these limits, and also when significant kidney disease 
is present, direct transfer of elevated pressures to the glomerular capillaries results in glomerular 
hypertension and the potential for glomerulosclerosis.  
The pathogenesis of feline hypertension remains poorly understood and will vary with differing 
aetiologies. Altered renal function, RAAS activation and pressure natriuresis likely play a role, but 
local factors (including local [tissue-specific] RAAS activation) are increasingly recognised as 
possible contributors.8 The good response seen in many hypertensive cats to the use of the 
vasodilator amlodipine5,6,9–15 suggests increased vascular tone may be a common component of 
feline hypertension. 
Figure 1: An overview of some of the important mechanisms involved 
in the regulation of blood pressure 
 
Classification of feline hypertension 
Hypertension is classified as:1 
• Idiopathic (or primary) where there is no apparent underlying disease, or 
• Secondary (thought to be due to underlying diseases or the use of therapeutic agents). 
‘White coat hypertension’ is the increase in BP that occurs as a consequence of excitement- or 
anxiety-related sympathetic activation. This is important in veterinary medicine as the neuro-
hormonal changes associated with the stress and/or excitement surrounding a veterinary visit can 
create a temporary physiological increase in BP.16,17 
Idiopathic hypertension 
Idiopathic hypertension is reported to occur in 13-20% of cats with hypertension.5–7 Further work is 
required to determine the degree to which non-azotaemic chronic kidney disease (CKD) might be a 
factor in some of these patients, and whether there are environmental factors or genetic 
predispositions as have been identified in humans with essential hypertension.18 
Secondary hypertension 
Secondary hypertension may be seen with many diseases including CKD, hyperthyroidism, primary 
hyperaldosteronism, hyperadrenocorticism, and phaeochromocytoma. Secondary hypertension is 
the most common form of hypertension seen in cats. 
Chronic Kidney Disease 
CKD is the most common condition associated with feline hypertension. Azotaemia has been found 
in up to 74% of hypertensive cats, and conversely between 19% and 65% of cats with CKD have 
been found to be hypertensive.19–22 However, the prevalence and severity of hypertension does not 
appear to be related to the severity of the CKD.2,19,23 
In humans, factors such as sodium and water retention, activation of RAAS and the sympathetic 
nervous system, structural changes to arterioles, endothelial dysfunction, oxidative stress and 
genetics all play a role in the pathogenesis of CKD-associated hypertension.8 
Less is known about the pathogenesis of hypertension in feline CKD, but the limited change in 
renin, aldosterone or BP in response to the use of angiotensin converting enzyme inhibitors 
(ACEi)24,25 suggests systemic RAAS activation is unlikely to be the major factor involved. Elevated 
aldosterone independent of RAAS activation is recognised in some hypertensive humans, and may 
also play a role in cats with hypertension.13,26 Some mechanisms worthy of investigation in cats 
with CKD-associated hypertension include local (tissue-specific) RAAS activation (independent of 
systemic RAAS), and impaired sodium handling by the tubules or collecting ducts18,27–29, although 
there is limited evidence to suggest salt sensitive hypertension exists in cats.30–32 The profound 
response of cats with CKD-associated hypertension to amlodipine5 suggests that increased vascular 
tone may be particularly important, although this has not been specifically investigated. 
Hyperthyroidism 
Hypertension has been documented in 10-23% of cats with hyperthyroidism at the time of 
diagnosis21,33–35, although some of these cats may also have had CKD. Additionally, nearly 25% of 
hyperthyroid cats normotensive at the time of diagnosis may develop hypertension after successful 
control of their hyperthyroidism.34–36 
The pathophysiology of hyperthyroid-associated hypertension remains poorly understood. Studies 
in other species suggest hyperthyroidism may increase cardiac sensitivity to circulating 
catecholamines, and thyroid hormones may also have direct effects on cardiac myocytes.37 
Hyperthyroidism may also decrease SVR (through direct and indirect effects on blood vessels) with 
subsequent stimulation of RAAS.38 However, in studies of hyperthyroid cats, there is no evidence 
that RAAS activation causes hypertension, although RAAS dysfunction may be present in some 
cats that develop hypertension after treatment for their hyperthyroidism.36 
Primary hyperaldosteronism 
Primary hyperaldosteronism (PHA) is an excess of aldosterone independent of its regulator, 
angiotensin II. Hypertension is reported in around 40-60% of cats with PHA39,40, and could initially 
be the consequence of sodium retention and volume expansion leading to increased CO, but 
sustained hypertension should result in pressure natriuresis returning plasma volume to normal. 
This, together with the fact that not all cats with PHA develop hypertension, suggest that other 
mechanisms are involved41, potentially including effects on blood vessels, vascular tone, vascular 
remodelling and responses to sympathetic stimulation.42–44 
Other diseases 
Diabetes mellitus (DM) is a well-recognised risk factor for hypertension in humans, but there is 
little current evidence to show the same is true of cats, although further work is needed. Severe 
hypertension in cats with DM appears uncommon7,45, and the prevalence of hypertension in cats 
with DM is typically low, but often confounded by the presence of concomitant conditions such as 
CKD.7,46 However, BP in cats with DM has been found to be higher than in healthy age-matched 
controls47, and hypertensive ocular disease has occasionally been reported in diabetic cats with no 
other underlying cause identified7, suggesting a link could exist. 
Phaeochromocytomas are rare tumours in cats48–52 associated with excessive circulating 
catecholamines, which can result in sustained or paroxysmal bouts of hypertension. There is also a 
report of severe hypertension in a cat associated with hyperadrenocorticism (HAC)53, although the 
prevalence of hypertension in cats with this disease is unknown. 
Consequences and clinical signs of hypertension  
Hypertension is most likely to cause disease in tissues with a rich arteriolar supply1,54, and in the 
cardiovascular system as a result of increased SVR.1,54 The eyes, brain, kidneys and myocardium 
are thus particularly vulnerable and hypertensive injury to these tissues is known as ‘target organ 
damage’ (TOD).1,20,54 Clinical manifestations of TOD can be striking and may be the reason for 
presentation to the veterinarian.7,20,55 However, TOD is not always present and in some cats clinical 
signs of their underlying disease may predominate5,19,56, or there may be no overt clinical signs. 
Target organ damage: eyes 
Hypertensive ocular changes have been reported in approximately 50% of hypertensive cats6,21,22,57, 
and studies suggest that retinal changes can develop at a SBP of approximately 160 mmHg and 
above.58,59 However, the high prevalence of reported ocular lesions may reflect the relatively late 
diagnosis of hypertension in many studies. 
The retina and choroid have separate blood supplies and both can suffer hypertensive damage60, 
with an array of fundic lesions visible on ophthalmoscopy:7,61 
• Hypertensive retinopathy can manifest as haemorrhages of varying size and number21,55 
(Figure 2) 
• Hypertensive choroidopathy can cause changes in the appearance of the retinal vessels.7  
Retinal oedema and breakdown of the blood-ocular barrier in the retinal pigment epithelium 
can create the impression that the vessels, particularly the arterioles, are narrowed61 (Figure 
3) 
• Hypertensive choroidopathy can also cause retinal detachment, which can appear bullous, 
flat, or may involve the whole retina61 (Figure 4), with the overlying retinal arterioles often 
appearing more tortuous than normal.61 Photoreceptors often sustain irreversible damage 
from retinal detachment.62 
• Hypertensive optic neuropathy is diagnosed rarely in cats, possibly because the nerve head 
appears recessed, making pathology more difficult to appreciate61 
Other ocular signs associated with hypertension include hyphaema and vitreal haemorrhage7, and 
hyphaema can lead to secondary glaucoma.55 
Many cats with severe hypertensive ocular damage present with blindness and bilateral mydriasis 
from complete retinal detachments and/or intraocular haemorrhage, with changes often 
irreversible.7,20,21 (Figure 5). Lesions that are not associated with impaired menace response or 
pupillary light deficits are much more amenable to antihypertensive treatment7, highlighting the 
importance of early diagnosis and management (Figure 6). Detection of early hypertensive ocular 
lesions requires an ocular examination to be performed on all cats at risk of developing lesions. 
Target organ damage: brain 
Hypertensive encephalopathy occurs when BP is high enough and sustained long enough to 
overcome the auto-regulatory ability of the cerebral vasculature.63 Cerebral oedema and 
arteriosclerosis have been described in cats with hypertensive encephalopathy.64,65 Studies have 
reported neurological signs in 15–46% of hypertensive cats7,20,57,66,67 including disorientation, 
seizures, ataxia, depression and vestibular signs. Confirmation that clinical signs are due to 
hypertension is rarely achieved without advanced imaging, but a presumptive diagnosis can be 
made if signs improve following normalisation of BP.65 Anecdotally, owners often report 
improvement in some behavioural signs (eg, depression, lethargy) after antihypertensive therapy. 
Target organ damage: heart and vasculature 
The elevated SVR associated with hypertension can increase left ventricular wall stress and result in 
concentric left ventricular hypertrophy (LVH). This may commonly produce auscultatory 
abnormalities such as gallop sounds, and perhaps less commonly murmurs and arrhythmias, in 
hypertensive cats.7,20,57 Echocardiography frequently reveals LVH57,68, although the degree of 
hypertrophy does not correlate with the magnitude of hypertension.69 Occasionally severe 
complications such as heart failure7,20, or aortic dissection70,71 have been reported in affected cats. 
Target organ damage: kidneys 
A recent controlled study72 demonstrated increased glomerulosclerosis and arteriosclerosis in cats 
with higher BP, supporting the concept of kidney TOD in feline hypertension. However, such 
lesions are not only caused by hypertension, and as many cats with hypertension have concomitant 
CKD, the importance of hypertension in causing nephrosclerosis and in causing or contributing to 
the progression of CKD remains uncertain.73 
There is an association between the systolic BP and the magnitude of proteinuria in cats with 
CKD74, and treatment with amlodipine reduces the proteinuria.6 This may be important as 
proteinuria has been linked to reduced survival in cats with either CKD74,75 or hypertension6, 
although managing hypertension has not yet been demonstrated to provide a survival benefit. In 
contrast, hypertension is recognised as both an important causal factor in human CKD, and a factor 
contributing to disease progression in human and canine CKD.8,76 
Patient groups benefiting from blood pressure measurement 
Hypertension is much more common in older cats (>10 years old) with current studies suggesting a 
median age at diagnosis of 13 to 15 years6,7,57, although it has been reported in cats as young as 5-7 
years.7,12,20,22,53,59,65 As early diagnosis (and management) of hypertension is considered valuable to 
help prevent TOD, these data help provide a rationale for which cats should undergo routine BP 
assessment. 
Additionally, as secondary hypertension is common in cats, individuals with recognised risk factors 
such as CKD, hyperthyroidism or PHA should undergo more frequent BP measurement.  Further, 
the presence of any unexplained disease compatible with hypertensive TOD (eyes, brain, kidney 
and heart) warrants careful BP assessment. 
Panel recommendations for monitoring BP in cats 
Recommendations for monitoring of SBP 
Category Frequency of SBP monitoring 
Healthy adult cats (3-6 years of age)  Consider every 12 months* 
Healthy senior cats (7-10 years of age) At least every 12 months 
Healthy geriatric cats (≥11 years of age) At least every 6-12 months 
Cats with recognised risk factors including: 
• Underlying diseases: CKD, 
hyperthyroidism (including treated cats), 
PHA, HAC, pheochromocytoma, etc. 
• Drug therapy: e.g. erythropoietin77,78 
• Evidence of TOD 
Measure immediately and re-assess 
at least every 3-6 months 
*  The main purpose in this age group is to obtain baseline measurements for the individual cat.  
As few cats in this age category have hypertension, great care is needed in the interpretation of elevated BP 
measurements, especially in the absence of TOD or a clear underlying disease 
 
Recommended equipment and procedures for measuring BP 
Direct assessment of BP (via arterial cannulation) accurately measures systolic BP (SBP), diastolic 
BP (DBP), and mean arterial pressure (MAP). Radio-telemetric implants allow direct BP 
measurements to be monitored over time in conscious animals, without direct intervention. 
However, this technique is not practical for clinical use in client-owned cats.54,79 
Equipment for routine clinical use 
In clinical settings and with conscious cats, BP is usually measured using indirect techniques such 
as Doppler sphygmomanometry or oscillometry. The Doppler technique has been extensively used 
in feline medicine, with investigators demonstrating good correlation and accuracy compared with 
direct BP assessment.80 It has been shown that traditional oscillometry is less accurate than Doppler 
in conscious cats, often underestimating BP at higher values, and there are many cats where it is 
difficult or impossible to achieve BP measurements with this equipment.80–85 
Recently, high-definition oscillometry (HDO) equipment has been developed to overcome the 
problems with traditional oscillometry. Although there are fewer reports of its use in cats, it has 
been compared to direct BP assessment in conscious cats over a range of different BPs and shown 
to provide accurate results.86 It also appears there are fewer cats where it is difficult to obtain a 
reading compared with traditional oscillometry.86,87 Notably, neither the Doppler nor HDO 
technique has been fully validated according to the ACVIM 2007 criteria.1,88 Although HDO 
equipment will generate figures for SBP, DBP and MAP, it has been shown that in conscious cats it 
is only the SBP value that has acceptable accuracy.86 Further, although DBP can be measured with 
the Doppler equipment, this measurement also lacks acceptable accuracy and repeatability.80,89 
However, systolic hypertension is generally thought to be the most clinically important form of 
hypertension, and although isolated diastolic hypertension may occur in cats1, the limitations of 
current measurement methodologies make this challenging to diagnose and any clinical significance 
uncertain. 
As in other species, BP in cats is labile and varies considerably within and between individuals, 
depending in part on their level of arousal, activity or stress.16,79,90 Clinical assessment of SBP is 
also affected by many external variables including the operator, conditions, environment, 
equipment, position of the cat, size of the cuff, and site of measurement.16,17,80,81,87,89,91–94 
Panel recommendations on use of equipment and procedures 
1. For assessment of BP and hypertension in conscious cats, either Doppler 
sphygmomanometry or HDO equipment should be used 
2. Only SBP measurements should be used for clinical assessment (DBP and MAP readings 
are less accurate and should generally be ignored) 
3. Use of standardised protocols (see box for panel recommendations) is imperative to 
improve the accuracy and reproducibility of measurements 
  
Panel recommendations for standardised protocols to assess SBP in cats 
1. Environment:  
• The cat should be in a calm quiet room, away from other animals 
• In a calm and quiet environment, SBP can sometimes be measured in hospitalised cats while they are in their cage 
• Have the cat resting on its own bedding (with its own scent) and/or consider using a synthetic facial pheromone (Feliway®) in 
the environment or on the bedding which may help reduce stress95 
2. Acclimatisation:  
• Allow the cat at least 5–10 minutes in the room to acclimatise17 
• The cat should be free to explore the room and interact with people 
• A cat carrier with a removable top will allow the cat to stay in the bottom of the carrier if it prefers 
3. Personnel:  
• Use the minimum number of people necessary (usually two) 
• Having the owner present may be valuable it they are able to reassure the cat in a quiet, gentle way 
• Having a trained, experienced individual measure SBP improves its reproducibility89 
• A nurse or technician who is empathetic with cats may often be the best person to measure SBP 
4. Restraint and positioning of the cat:  
• Using minimal and gentle restraint is vital 
• Cats should be in a settled, relaxed, comfortable position  
• If the cat becomes agitated, stop and let it settle rather than using firmer restraint 
• Try to keep the cat in the same position throughout the procedure 
• Avoid measuring BP while the cat is moving 
5. Choice and position of cuff:  
• The cuff width for cats should be 30–40% of the circumference of the limb/tail where it is used93 
• The site for BP measurement will depend partly on what is tolerated best by the cat, but the forelimb may be better for Doppler 
measurements91 while the tail is better for HDO87 
• Handle and manipulate limbs gently – older cats especially may suffer from osteoarthritis 
• Where possible, the site of BP measurement should be roughly on the same horizontal plane as the heart 
• Cuffs are usually secured with a Velcro fastener, fit them snugly but avoid restricting blood flow. A small piece of adhesive tape 
may also be used if necessary, but this should never be wrapped around the limb/tail 
6. Using Doppler equipment 
• Detection of blood flow requires good contact between the Doppler probe and the skin - this is best achieved with alcohol to 
dampen the hair and skin, and the use of plenty of ultrasound gel (figure) 
• Clipping the hair at the site is not usually necessary. It may be considered if detection of blood flow is difficult, but use quiet 
clippers and allow the cat time to settle before measuring BP 
• Ensure the inflatable portion of the cuff is positioned over the artery to be occluded 
• Using headphones to avoid sound from the Doppler unit disturbing the cat is highly recommended; if not available ensure the 
volume is turned down when the procedure starts, and use the lowest volume needed to hear pulsatile blood flow 
• Position the Doppler probe with gentle pressure to avoid restricting blood flow, and adjust the position slowly until pulsatile 
blood flow is heard 
• Inflating and deflating the cuff a few times before making recordings helps the cat get used to the sensation 
• Slowly inflate the cuff to 20-40 mmHg above the point where blood flow is no longer heard 
• Allow air to slowly bleed from the cuff – SBP is the point when pulsatile blood flow is first detected 
7. Using HDO equipment 
• Patient movement can readily cause false SBP readings - using the tail and ensuring the cat is as still as possible helps to reduce 
this error86,87 
• The area where the inflation tube enters the cuff should be placed closest to the artery, as this maximises the sensitivity of the 
HDO equipment 
• When the machine is activated, the cuff will automatically inflate and deflate at a constant rate, and BP values will be generated 
- only the SBP should be used 
• The HDO should always be linked to a PC or tablet computer – this allows checking that the deflation of the cuff is steady and 
that the pulse waves are smooth, with an outline approximating a bell-shaped curve. If these criteria are not met, the reading 
should be discarded as unreliable (eg, due to movement artefact) (figure) 
8. Measuring BP:  
• The first SBP measurement is usually discarded, subsequently ideally 5–7 consecutive and consistent (<20% variability) 
measurements should be made and SBP calculated as the mean of these 
• All readings should be recorded whether used to calculate SBP or not 
• If there is a consistent downward (or upward) trend in readings or ≥20% variation, further measurements should be made until 
consistent readings are achieved, using only the consistent readings to calculate the average SBP 
• If there is doubt over SBP validity, the procedure should be repeated - either immediately, after further acclimatisation, or later. 
Consider also changing the placement of the cuff, and reassess the environment for causes of stress 
9. Consistency:  
• Careful records should be kept (Figure 7) 
• For meaningful SBP comparisons in a cat, the assessment should be replicated using the same equipment, personnel and 
procedures as far as possible each time 
International Cat Care have produced a set of videos (in various languages) on measuring blood pressure – these can be accessed by 
going to www.youtube.com/user/iCatCare and searching for ‘blood pressure’   
Figure: Example of a blood pressure assessment form 
 
 
Defining normal blood pressure 
Some studies have evaluated direct SBP, DBP and MAP in healthy cats using radio-telemetry 
(Table 1), the results of which were not dissimilar to other mammalian species, including 
humans.16,79,90,96 These studies also highlight the lability of feline BP in individual cats with one 
demonstrating up to 80 mmHg change in SBP in response to a simulated clinic visit16, showing the 
potential magnitude of ‘white-coat hypertension’ in healthy cats.  
Table 1: Direct BP measurements (mmHg) in studies of healthy 
conscious cats 
Study and number of 
cats 
SBP 
mean ±SD 
MAP 
mean ±SD 
DBP 
mean ±SD 
Brown et al (n=6)96 
Belew et al (n=6)16 
Slingerland et al (n=21)79 
Mishina et al (n=16)90 
125±11 
126±9 
132±9 
117±12 
105±10 
106±10 
115±8 
94±11 
89±9 
91±11 
96±8 
78±10 
Establishing reference ranges of estimated SBP in healthy cats using Doppler or oscillometric 
equipment is fundamental to both the clinical diagnosis of hypertension, and also in determining 
therapeutic targets in affected cats. Results of studies in healthy cats are shown in Table 2, but it 
should be noted that there is a wide discrepancy between different studies reflecting, at least in part, 
the different populations examined, and differences in types of equipment used and the way 
equipment was used. Thus having a standardised technique is of paramount importance. 
Unlike in humans, to date in feline medicine no gender or breed effects on BP have been 
identified56,94, but similar to humans a recent large longitudinal study of cats established a small but 
significant increase in BP as cats age2, equating to ~1-2 mmHg per annum for cats >9 years old. 
Humans with higher baseline BPs may be at higher risk for the future development of hypertension 
(termed pre-hypertension)99–101, and there is evidence that the same may also be true of cats.2 
Table 2: Indirect SBP (mmHg) measurements in 
studies of healthy conscious cats 
Equipment used and number of cats SBP: mean (±SD) 
Traditional oscillometric*  
Bodey & Sansom (n=104)56 
Mishina et al (n=60)94 
Curter et al (n=72)92 
Morar et al (n=54)97 
Haberman et al (n-13)80 
139 (±27) 
115 (±10) 
123 
124 
133 (±28) 
Doppler sphygmomanometry  
Kobayashi et al (n=33)19 
Sparkes et al (n=50)17 
Lin et al (n=53)98 
Bijsmans et al (n=124)2 
Conti et al (n=30)91 
Haberman et al (n=13)80 
118 (±11) 
162 (±19) 
134 (±16) 
131 
135 (±21) 
146 (±50) 
* Note traditional oscillometry not suitable for assessing clinical hypertension as it tends to 
under-estimate BP at higher values, and produces readings less reliably – see text 
The majority of cats reported in the literature to have TOD associated with hypertension have had 
indirect SBP measurements in excess of 160 mmHg5,7,14,20,22,53,55–57,59,64,65,71,102, although there are 
occasional exceptions to this.58 The International Renal Interest Society103 (IRIS) has proposed four 
categories of BP in cats to help with the diagnosis of hypertension based on potential risk of TOD 
(Table 3). However, along with the lability of BP already noted, it is likely the TOD damage in 
hypertension will not only be related to the severity of the hypertension, but also to the duration and 
relative change in BP that occurs, thus strict categorisation is problematic. 
Table 3: International Renal Interest Society staging for BP103 
SBP (mmHg) Category Risk of TOD 
<150 Normotensive Minimal 
150-159 Borderline hypertensive Low 
160-179 Hypertensive Moderate 
≥180 Severely hypertensive High 
Panel recommendations on criteria justifying anti-hypertensive therapy 
While individual circumstances should always be carefully assessed, based on current knowledge 
the panel suggests that in general anti-hypertensive therapy is justified if SBP is measured carefully 
(see above) and when: 
1. Indirect SBP is ≥150 mmHg on a single occasion, and there is clear evidence of ocular or 
neurological TOD. If clinical signs do not respond appropriately to adequate anti-
hypertensive therapy, the diagnosis should be reassessed and other potential causes of the 
signs investigated 
2. Indirect SBP is ≥160 mmHg on at least two separate occasions, and there is evidence of 
TOD including ocular, neurological, cardiac or kidney damage 
3. Indirect SBP is ≥170 mmHg on at least two separate occasions, and the clinician does not 
consider ‘white coat hypertension’ is likely to be the cause 
4. Indirect SBP is <150 mmHg but where there is clear evidence of active ocular TOD. Cats 
should be monitored carefully – if there is any doubt about the diagnosis of hypertension the 
need for long-term therapy should be re-assessed by trial withdrawal of therapy once stable, 
and monitoring of BP and clinical signs. 
Cats with evidence of potential TOD that have SBP <150 mmHg should have their clinical signs 
and BP monitored carefully, and other potential causes of the signs investigated 
Panel recommendations on investigation of hypertensive cats 
Along with measuring SBP, when hypertension is diagnosed cats should be carefully evaluated for 
both TOD and the presence of underlying disease. Assessments should include: 
• Complete physical examination (including thorough cardiac, neurological and ocular 
assessment, including indirect ophthalmoscopy) and thorough clinical history. Indirect 
ophthalmoscopy is a very valuable technique and readers are referred elsewhere for full 
details.104 
• Laboratory evaluation to identify any underlying disease(s): 
- Serum creatinine and/or SDMA 
- Urinalysis, including specific gravity and quantitative proteinuria assessment 
- Serum thyroxine 
- Serum sodium, potassium and chloride 
• Additional investigations that may be of value include: 
- Diagnostic imaging (cardiac and abdominal imaging) 
- Serum aldosterone (ideally with measurement of renin or renin activity) 
- Further endocrine testing where appropriate (eg, dynamic adrenal function testing, 
glucose monitoring etc.) 
Routine treatment of hypertension 
Whenever hypertension is diagnosed, it is important to search for, and treat, underlying diseases as 
most cases of feline hypertension are secondary. However, treatment of underlying diseases is 
outside the scope of these guidelines, and does not obviate the need for appropriate anti-
hypertensive therapy. 
The goal of therapy for hypertension is to decrease the risk of TOD, and to help maintain or 
improve the health of the cat. This is generally achieved with an initial target SBP of <160mmHg1, 
although the IRIS group103 suggest the risk of TOD is minimal if SBP is <150 mmHg, and as some 
cats with TOD have pressures below 160 mmHg, a target of <150 mmHg may be an appropriate 
long-term goal. 
Amlodipine besylate 
Based on current data5,6,9,11,12,14,66, the dihydropyridine calcium channel blocker amlodipine besylate 
is the drug of choice for the management of hypertension in cats, and there is now a product 
licensed for feline use in some countries.  
Amlodipine is a potent peripheral arterial dilator that acts directly on vascular smooth muscle 
causing a reduction in SVR and BP with minimal cardiac effects.15 The reduction in SBP following 
treatment of hypertensive cats is generally around 30-70 mmHg5,6,11,12,14,66, with 60%-100% of cats 
responding to amlodipine as a monotherapy, albeit with dose adjustment being needed in 
some.5,6,9,12,14 Amlodipine has also been shown to reduce the magnitude of proteinuria in 
hypertensive cats with CKD.6,74 Adverse events associated with amlodipine therapy appear 
uncommon.12,15 Although hypotension is a rare complication5,15, monitoring of SBP is always 
recommended.15 
Amlodipine has typically been used orally, at a starting dose of 0.625mg/cat (or 0.125mg/kg ) q24h, 
with doubling of the dose if response is inadequate within 1-3 weeks.5,6,9,11,12,14,66 The reduction in 
SBP appears to be dose-related9,105, and thus cats with a higher SBP (eg, ≥200 mmHg) may benefit 
from starting at the higher dose (1.25 mg/cat or 0.25 mg/kg q24h).9,105 Infrequently, higher doses 
(up to 2.5 mg/cat or 0.5 mg/kg q24h) of amlodipine may be needed12, but compliance should be 
checked as few cats appear to require these doses.5,6,9,11,12,14,66 Transdermal amlodipine has also 
been used in cats67, but may be less effective than oral therapy and further studies are required to 
determine optimum dosage and formulation. 
Other treatments 
Angiotensin converting enzyme inhibitors24,25,106–108, angiotensin receptor blockers (ARB)107 and 
beta-blockers4 have all been used to treat feline hypertension, but they appear to have poorer 
efficacy in reducing SBP than amlodipine (typically only a reduction in SBP of 10-20 
mmHg24,25,106–109), and fewer cats respond adequately to their use as monotherapy. These drugs are 
therefore best considered as second (or rarely third) agents to add in to therapy if treatment with 
amlodipine is not sufficent to control the SBP110 (Table 4), or if their use is dictated by any 
concurrent or underlying disease. 
The choice of adjunctive therapy to help manage hypertension may in part be dictated by any 
concurrent or underlying disease. For example, ACEi or ARBs may be indicated in CKD patients to 
help manage proteinuria, atenolol may be indicated in some hyperthyroid cats to manage 
tachycardia, prazosin (an alpha adrenergic blocker) may be indicated in pheochromocytoma, and 
spironolactone in hyperaldosteronism. These drugs are usually combined with amlodipine and 
titrated to effect.  
Table 4: Drugs used for management of hypertension 
Drug Suggested dose Comment 
Amlodipine  0.625 – 1.25 mg/cat q24h PO or 
0.125 – 0.25 mg/kg q24h PO 
Calcium channel blocker and drug of first 
choice. Dose may be doubled if response is 
inadequate up to a maximum of 0.5 mg/kg or 
2.5 mg/cat q24h1,12 
Benazepril 0.5-1.0 mg/kg q24h PO ACEi24,25,108,110 
Enalapril 0.5 mg/kg q12-24h PO ACEi24,25 
Ramipril 0.125-0.25 mg/kg q24h PO ACEi111 
Telmisartan 1 mg/kg q24h PO 
(experimentally, a dose of 3 
mg/kg exhibited a greater effect 
on blood pressure) 107 
ARB, licensed at 1mg/kg q24h in some 
regions for management of CKD-associated 
proteinuria. Not assessed clinically for 
managing feline hypertension but greater 
response than benazepril to angiotensin I-
induced pressor response when given at 1-3 
mg/kg107 
Atenolol 1-2 mg/kg q12h PO β-blocker 109 
Panel recommendations for routine therapy and monitoring 
1. Routine treatment of cats with hypertension should commence with amlodipine at 0.625 
mg/cat (or 0.125 mg/kg) q24h 
2. For cats with a SBP ≥200 mmHg, consideration should be given to commencing therapy at 
1.25 mg/cat (or 0.25 mg/kg) q24h 
3. Cats with evidence of TOD at the time of diagnosis and/or cats with SBP ≥200 mmHg 
should have their BP and clinical signs monitored closely during the first 24-72 hours. For 
some cats (eg, those with overt hypertensive encephalopathy or severe cardiac 
complications) hospitalisation may be required to allow close monitoring and control of the 
SBP. In other cases, initial daily re-evaluation may be sufficient. See also ‘Emergency 
treatment of hypertension’ below. 
4. Cats without evidence of TOD should initially have their SBP reassessed at least every 7-10 
days (depending on severity, concomitant disease etc.), together with evaluation of clinical 
signs (including thorough ocular examination). Re-evaluation of laboratory parameters may 
also be prudent at this time, depending on the presence and severity of concomitant disease. 
5. If response to therapy is inadequate, amlodipine dose can be doubled up to a maximum of 
2.5 mg/cat (or 0.5 mg/kg) q24h. Dose increases are generally made at intervals of 7 days or 
more, but may be shorter (eg, after 24 hours) if the SBP is high (≥200 mmHg) or there is 
ongoing TOD (see ‘Emergency treatment of hypertension’, below). 
6. If response to amlodipine is inadequate, or if concomitant disease suggests another 
antihypertensive agent would be useful (eg, persistent proteinuria), a second drug can be 
added together with the amlodipine 
7. The short-term (ideally within 1-2 weeks) aim of therapy should be to reduce SBP to <160 
mmHg. In the longer-term (weeks) aiming for a SBP of <150 mmHg may be prudent to 
minimise any risk of TOD. A safe lower limit for indirectly measured SBP in cats on anti-
hypertensive therapy has not been well established, but the panel recommend SBP should be 
kept above 110 mmHg. 
8. Once BP is controlled in cats, SBP should be reassessed at least every 3 months. Along with 
SBP measurement, clinical signs of TOD should be monitored (ocular examination, 
neurological examination and cardiac auscultation ± echocardiography); and laboratory tests 
re- evaluated (eg, serum creatinine and/or SDMA concentrations, urinalysis with UPC ratio, 
assessment of other parameters as indicated). Fundic examination with indirect 
ophthalmoscopy104 provides the easiest way to monitor the progress of ocular TOD with 
antihypertensive treatment (Figures). Once SBP is controlled there should be no further 
progression of lesions, but existing fundic lesions may take weeks to months to show 
improvement (depending on the presenting severity of the lesions and the control of SBP). 
Mild fundic lesions (eg, retinal oedema and small bullous lesions) respond better to anti-
hypertensive treatment than advanced lesions do (eg, retinal detachment, severe retinal 
haemorrhage).7,58 
 
Emergency treatment of hypertension 
Rationale for emergency treatment 
Hypertension is generally a chronic condition, although some cats may present with an acute onset 
of severe clinical signs associated with TOD (usually ocular, neurological or cardiovascular). Acute 
elevations of BP may also be seen in some diseases such as acute kidney injury. Although 
hypertensive emergencies are not as clearly established as in humans112, the severity of TOD may 
prompt more aggressive anti-hypertensive therapy1,113, even though there is a lack of definitive 
evidence that this approach is any more beneficial, and the risks of adverse events could be 
greater.114 
Emergency treatment is aimed at halting ongoing TOD and preventing further damage. In human 
medicine, the initial goal of emergency therapy is to smoothly reduce SBP by up to 25% in the first 
1-2 hours, and then towards a level of 160 mmHg within a total of 6 hours.99 Uncontrolled, abrupt 
reduction in SBP or development of hypotension can precipitate myocardial, cerebral, or renal 
ischemia and should be avoided.115,116  
Cats requiring emergency therapy should be hospitalised for close monitoring of BP and treatment 
adjustments. Where feasible, direct arterial pressure monitoring is preferred, to provide the most 
accurate measurement of BP. Generally, anti-hypertensive agents (especially parenteral agents) 
should be titrated upward to effect.117,118 Amlodipine monotherapy may still be effective in 
emergency situations and	should be used whenever oral administration is possible, safe and likely to 
be adequate. Detailed pharmacokinetic data of amlodipine use in cats are lacking, in humans peak 
serum concentrations occur after 6-8 hours119 and data provided for licensing in cats suggests it has 
peak serum concentrations at 3-6 hours in this species, with a half-life of 53 hours.120 It has also 
been reported to have a BP lowering effect within 4 hours and to last up to 30 hours in clinical 
cases.10 Parenteral treatments may need to be considered if the oral route cannot be used, if 
response to oral therapy is inadequate, or if an underlying disease dictates their use. 
Table 5: Parenteral drugs that can be used for emergency management 
of hypertension 
Drug Suggested dose Comment 
Hydralazine 0.2-0.5 mg/cat SQ, repeat after 
15 min if necessary 
Direct arterial vasodilator. Add a β-
blocker if reflex tachycardia 
occurs1,102,113 
Acepromazine 50-100 µg/cat IV or SC Phenothiazine and alpha-blocker, non-
specific vasodilator102,118 
Nitroprusside 1 µg/kg/min CRI; titrate up to 3 
µg/kg/min if needed  
Nitric oxide donor, non-specific 
vasodilator113 
Labetolol 0.25 mg/kg IV over 2 min, repeat 
up to a total of 3.75 mg/kg, then 
25 mg/kg/min as CRI 
α and β-blocker1 
Esmolol 50–100 mg/kg/min CRI β-blocker1,113 
Panel recommendations 
1. Hypertensive emergencies are those cats with hypertension and evidence of (or at high risk 
of) acute, severe and progressive TOD 
2. Affected cats should be hospitalised and their SBP should be monitored frequently and 
carefully (eg, every 4 hours until the target SBP is achieved and then 2-4 times daily until 
stable).  
3. Whenever possible oral amlodipine should be administered immediately at a starting dose of 
0.625-1.25 mg/cat (or 0.125-0.25 mg/kg), depending on the severity of both clinical signs 
and SBP. 
4. The dose of amlodipine could be repeated after 4-8 hours if necessary, in increments up to a 
maximum of 2.5mg/cat in the first 24 hours 
5. If oral amlodipine cannot be used or if additional therapy is required, short-acting parenteral 
anti-hypertensive drugs can be administered (Table 5) 
6. Once the cat is stable, standard treatment should be instituted (see ‘Panel recommendations 
for routine therapy and monitoring’ above) 
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